RRMS
Sanofi reveals promising data for relapsing remitting MS treatment
September 20, 2016Manufacturing and Production, Research and Development RRMS, Sanofi, relapsing remitting multiple sclerosis, relapsing-remitting multiple sclerosis
Sanofi Genzyme, the speciality care global business unit of the French pharma firm announced six-year investigational data on Lemtrada (alemtuzumab) …
Genzyme’s Lemtrada shows five-year efficacy in extended trials
October 8, 2015Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis
Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …
NICE final ‘yes’ for Biogen’s MS pill
August 27, 2014Sales and Marketing Aubagio, Biogen, RMS, RRMS, gilenya
In final guidance published today NICE has recommended NHS funding of Biogen Idec’s new multiple sclerosis pill in patients with …
